Kunena :: Тема: Posted by Holden on 29.11.2016 19:59:28: what is pulsed tarceva (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by Holden on 29.11.2016 19:59:28: what is pulsed tarceva

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by Holden on 29.11.2016 19:59:28: what is pulsed tarceva

Страница:
1
2

ТЕМА: Posted by Holden on 29.11.2016 19:59:28: what is pulsed tarceva

Posted by Holden on 29.11.2016 19:59:28: what is pulsed tarceva 7 года 5 мес. назад #927

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
ARCHER 1050 is an ongoing multicenter, randomized, open-label, Phase III study comparing dacomitinib to gefitinib in treatment-naïve advanced EGFR -mutant NSCLC patients harboring the common-activation EGFR mutations (exon 19 deletions and L858R substitution). The presence of T790M is allowed as long as one of the two common EGFR mutations is also present. The primary end point is PFS, and randomization is one to one. This trial is being conducted only in Asia (People’s Republic of China, Japan, South Korea, Hong Kong) and Europe (Spain, Italy, Poland), and not in North America. The goal of the trial is to show >50% improvement in median PFS in dacomitinib over gefitinib, with an estimated median PFS of erlotinib of 9.5 months and projected median PFS of dacomitinib to be at least 14.3 months. Stratifications are by type of EGFR mutation and ethnicity. 29 The trial schema are represented in Figure 1 .
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung

: an open-label randomised controlled phase 3 trial.
so-dialog.ru/index.php/forum/dobro-pozha...inib-and-lung-cancer
7/11: Mum 72 yr old, non-smoker, pleural effusion, dx NSCLC adeno EGFR+, ALK- 8-9/11: Started gem/cis 2 cycles 9/11 to 2/12: Tarceva; 2/12 pleuradeses 5/12: incorrect EGFR test caused onc to move to carbo/alimta/avastin 4cycles+ avastin/alimta 6 cycles 1/13: corrected EGFR test brought to Afatinib+ erbitux biweekly; fullness/tightness on stomach 9/13: cetuximab toxicity, on Afatinib alone
"Our results showed that first-line erlotinib nearly doubled progression-free survival; that's a significant improvement over chemotherapy, with a better tolerability profile," Gervais said in the news release.
3 Pao W. Miller V. Zakowski M et al . EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004 ; 101. 13306 – 11.
alschool.kiev.ua/index.php/component/kun...ceva-nccn-guidelines
Múltiples estudios han analizado de forma retrospectiva el valor de las mutaciones del gen EGFR en pacientes con CPNM avanzado tratados con gefitinib o erlotinib. En estos estudios se encontró que los pacientes de raza asiática, sexo femenino, histología de adenocarcinoma y no fumadores o fumadores de menos de 100 cigarrillos en total, obtenían mejores tasas de respuesta al utilizar un inhibidor de la tirosina cinasa del EGFR. De forma retrospectiva, parecía que este perfil clínico se correspondía con la presencia de mutaciones activadoras. Así, por ejemplo, en un estudio con gefitinib 22 la tasa de respuestas parciales fue del 64,7% en pacientes con mutación del EGFR comparada con sólo el 13,7% en pacientes sin mutación. También la supervivencia libre de progresión (SLP) y la SG fueron superiores en los mutados (21,7 frente a 1,8 meses de SLP y 30,5 frente a 6,6 meses de SG). Todo ello generó un gran volumen de información, que, como siempre, debía confirmarse en ensayos prospectivos, como así ha sido.
Moore, M. J. D. Goldstein. J. Hamm. A. Figer. J. R. Hecht. S. Gallinger. et al. 2007. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25. 1960 – 1966.
Table I. Symptoms and interventions of most common erlotinib-related skin disorders by severity
Drug: Erlotinib Radiation: concurrent brain radiotherapy Radiation: secondary brain radiotherapy
forum-molokovo.ru/forum/d-orlovo/2110-po...g-precio-mexico.html
"Erlotinib is very effective and well tolerated in advanced NSCLC patients who harbor EGFR activating mutations. It is 2 to 3 times more effective than doublet chemotherapy," said study leader Professor Caicun Zhou of Shanghai Pulmonary Hospital, Tongji University, China.
By univariate analysis for PFS, age ≤60 years ( P = .003), female sex ( P < .001), ECOG PS of 0-1 ( P = .014), adenocarcinoma histology ( P = .001), number of prior systemic chemotherapy ≤2 ( P < .017), never smoker status ( P < .001), and absence of intra-abdominal metastasis ( P < .001) were associated with prolongation of PFS. As previously stated, treatment group (neither gefitinib nor erlotinib) did not influence PFS. In multivariate analysis of PFS, age ≤60 ( P < .001), adenocarcinoma histology ( P = .029), and absence of intra-abdominal metastases ( P = .002) were independent factors associated with longer of PFS for all 342 patients (Tables 5 ).
Only one patient had disease progression while on adjuvant erlotinib, and 10 experienced progression at least 6 months after stopping the drug, suggesting the presence of residual disease that may be sensitive to re-treatment with erlotinib, Dr. Neal said in an interview.
russkazka.com/forum/9--/2459-posted-by-e...s-tarceva-rash-start
Tarceva 25 mg filmomhulde tabletten
The trial closed to enrollment at about 60% of its target enrollment, due to these various challenges, but it still accrued 253 patients, which was enough to draw some conclusions. The trial didn’t really show any surprising issues with side effects, and unfortunately it also didn’t show any survival benefit for the maintenance Tarceva. Both arms did pretty well, with the median OS 26.9 months on the placebo arm, and 23.6 months on the Tarceva arm:
Orifarm GmbH Filmtabletten | 30 ST 93.81 €/Stück PZN: 3031277 ab 2814.41 € Tarceva 150mg Filmtabletten 30 ST
Jus de pamplemousse : le jus de pamplemousse peut nuire à l’élimination de l’erlotinib par le foie, ce qui provoque une augmentation des effets secondaires. Les personnes qui prennent ce médicament ne devraient pas boire du jus de pamplemousse.
Hallo Dawn. I agree with Janine that is feeble for your doctor to duck these questions. Like your husband, I am stage IV and have coughed up a lot of blood in the last two and a half years, mostly before I was on Tarceva (I don’t think there’s any connection there). Coughing up blood is common in lung cancer, but not “normal”. The technical term is hemoptysis. It can mean lots of things, not all of them bad but should definitely be assessed promptly by a doctor. Generally speaking, the older the blood, the darker it is. The sliminess will be mucus. The liverish bits are bits of tissue. I’ve had that too. It’s quite unnerving but not dangerous in itself, unless the bleeding goes on and on. I hope it is not bothering your husband too much. Once I got used to the blood I found it was more frightening for the people around me (like you with your husband) than it was for me. And no, it doesn’t tell you how long he has to live. Where I am (UK) this would be a job for a respiratory physician (pulmonologist), not an oncologist. I’m sorry you’re both having to go through this. Very best. PS – this is what Dr West had to say about it a couple of years ago: “Hemoptysis is most typically caused by a tumor invading a nearby blood vessel that is also near a branch of the bronchial tree. It may also be from a blood vessel that is part of the cancer eroding.” Sorry, this stuff is not very nice to hear.
Tarceva, nouveau médicament contre le cancer du poumon, reçoit sa première homologation en Europe
The failure of combination chemotherapy to improve outcomes in pancreatic cancer means we need to look at alternate systemic approaches to this disease. Combinations of gemcitabine with the anti-EGFR monoclonal antibody, cetuximab, and with the anti- vascular endothelial growth factor antibody, bevacizumab, do show promise in phase II studies. 29 ,35 Both approaches are currently in phase III testing versus single-agent gemcitabine in the North American cooperative groups. The recent announcement that the gemcitabine plus bevacizumab trial did not meet its primary end point of improved survival is a reminder of the difficulties of improving outcomes in pancreatic cancer. Other phase II studies are exploring other targeted agents in combination with gemcitabine, or multiple targeted agents in combination with chemotherapy. The recent demonstration of benefit from chemotherapy in the adjuvant setting suggests that studies of erlotinib after surgery for localized disease may also be warranted. 36 ,37
chitogrito.ru/index.php/forum/3-nebolsha...3909-tarceva-2-linea
24 Mar 2012. Anuncios clasificados en Universidades - VENDO Tarceva 150 mg. 14000. INF. OSCAR 43270944.92*11*20935.
Drug resistance is one of the major problems of chemotherapy. Potential mechanisms of drug resistance include the activation of Ras/Raf/Mek/ERK signal transduction cascade and the increase of cholesterol levels in cancer cells, both being controlled by isoprenoids.32 The production of isoprenoids is catalyzed by HMG-CoAR which may therefore be a rational molecular target for innovative antineoplastic treatment of esophageal cancer. Fluvastatin is an effective inhibitor of HMG-CoAR and has already been shown to inhibit tumor cell growth.33 Here we demonstrate the antineoplastic effect of fluvastatin alone and in combination with erlotinib in esophageal cancer cells. Moreover, fluvastatin synergistically enhanced the antiproliferative effect of erlotinib. Hence, combining erlotinib and fluvastatin is a promising approach for dual targeting treatment strategies in esophageal cancer disease. Further investigations will be conducted to clarify the exact mechanisms underlying the observed overadditive growth inhibitory effects.
Hepatorenal syndrome, severe acute renal failure including fatal cases, and renal insufficiency can occur with TARCEVA treatment. Renal failure may arise from exacerbation of underlying baseline hepatic impairment or severe dehydration. The pooled incidence of severe renal impairment in the 3 monotherapy lung cancer studies was 0.5% in the TARCEVA arms and 0.8% in the control arms. The incidence of renal impairment in the pancreatic cancer study was 1.4% in the TARCEVA plus gemcitabine arm and 0.4% in the control arm. Withhold TARCEVA in patients developing severe renal impairment until renal toxicity is resolved. Perform periodic monitoring of renal function and serum electrolytes during TARCEVA treatment [see Adverse Reactions and Dosage and Administration] .
Is it possible to have focal treatment to the one tumor that’s causing all the change. That’s the trending treatment for those on 1st gen tki like tarceva but not 3 gen tagrisso. Plus I don’t know if it’s possible to use sbrt for the liver but it may be worth the conversation with the onc. We have tons written on the subject. cancergrace.org/lung/acquired-resistance...t-forum-2014-videos/
Les EI les plus fréquemment observés chez les patients traités par Tarceva dans l'étude ML20650 ont été des éruptions cutanées et des diarrhées (tout grade, respectivement 80% et 57%), la plupart étaient de grade 1/2 et n'ont pas nécessité d'intervention spécifique. Des éruptions cutanées et des diarrhées de grade 3 sont survenues chez respectivement 9% et 4% des patients. Aucune éruption cutanée ou diarrhée de grade 4 n'a été observée. Une sortie d'étude en raison d'éruptions cutanées ou de diarrhées est survenue chez 1% des patients. Une modification (arrêt ou réduction) de la posologie en raison d'une éruption cutanée ou d'une diarrhée a été nécessaire chez respectivement 11% et 7% des patients.
din-almaty.gov.kz/index.php?option=com_k...2&Itemid=719&lang=ru
Erlotinib inhibits growth of the chordoma PDX.
Thank you Dr. West for your helpful response. It makes sense that she shouldn’t feel much worse on treatment. She ended up needing to go to the ER and had a thoracentisis of 2 liters. We don’t know how long the fluid was building up after her last chemo 4 weeks ago and whether it was already building before the Tarceva. She only seems to get uncomfortable after 1.5 liters when she had this issue prior to chemo. It looks like we will have to wait and see what happens and stay in touch with her doctor over the next week. We really hope that there is still a chance Tarceva will work.
Mok TS, Lee J, Zhang L, et al. Biomarker analyses and overall survival (OS) from the randomized, placebo-controlled, phase 3, FASTACT-2 study of intercalated erlotinib with first-line chemotherapy in advanced non-small-cell lung cancer (NSCLC). Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2012;23:ix400-ix46.
Eligible patients had advanced cholangiocarcinoma or gallbladder cancer. Patients were treated with bevacizumab 5 mg/kg intravenously on days 1 and 15 and erlotinib 150 mg by mouth daily on days 1 through 28. Responses were evaluated by RECIST. VEGF levels were collected, and samples were analyzed for EGFR mutation by polymerase chain reaction.
After oral erlotinib administration to wild-type and ATP-binding cassette (ABC) transporter-knockout mice ( Mdr1a/b −/−. Abcg2 −/−. Mdr1a/b −/− Abcg2 −/−. and Abcc4 −/− ), plasma was collected and brain extracellular fluid (ECF) was sampled using intracerebral microdialysis. A pharmacokinetic model was fit to erlotinib and OSI-420 concentration-time data and brain penetration ( P Brain ) was estimated by the ratio of ECF-to-unbound plasma area under concentration-time curves. Intracellular accumulation of erlotinib was assessed in cells overexpressing human ABC transporters or SLC22A solute carriers.
www.elnit.org/index.php?option=com_kunen...=3&id=831&Itemid=312
ERLOTINIB tablete IP 150 mg Erlocip150 ( zamena za Tarceva-u )
Age of people who have Loss Of Taste when taking Tarceva *:
"Not only does [Tarceva] help them live longer. but it also improves their physical function, their quality of life, and it improves the symptoms of cough. shortness of breath, and pain," she continues.